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Improvements in patient self-assessment and declines in B-
type natriuretic peptide levels with levosimendan persisted
for 5 days and were associated with reduced length of
hospital stay (p ¼ 0.009). However, levosimendan was
associated with more frequent hypotension and cardiac
arrhythmias during the infusion period and a numerically
higher risk of death (p ¼ 0.29). An excess risk of deaths in
the levosimendan group was apparent as early as 5 days;
was nominally significant at 14 days, and was largely seen
in subgroups at highest risk of death before entry into
the study (eg patients with systolic blood pressure
<100 mmHg). After 90 days, the relative risk of death
(levosimendan/placebo) was 1.9 in patients with a pre-
treatment systolic blood pressure <100 mmHg but was 1.1
in patients with a systolic blood pressure >100 mmHg.
Conclusions: In patients with ADHF, intravenous levosi-
mendan provided rapid and durable symptomatic relief.
However, levosimendan was associated with an increased
risk of adverse cardiovascular events.1. Clinical perspective
Even though positive inotropic agents have immediate ben-
eficial hemodynamic effects in patients with systolic heart
failure, they do not improve outcomes in patients with ADHF.
In fact, the use of inotropes like dopamine and milrinone is
associated with a number of adverse cardiovascular events,
and may worsen patient outcomes in the long term. Unlike
other inotropic agents, levosimendan, a calcium sensitizer,
improves myocardial contractility without causing an
increase in myocardial oxygen demand and in addition has
vasodilator properties. Because of these unique properties
levosimendan has been a promising drug and previous small
trials in patients with ADHF have reported favorable effects
on symptoms, hemodynamics and even survival. The current
REVIVE trial was a relatively large trial that tried to confirm
these findings. In this trial patients who received levosi-
mendan had improvement in symptoms and reduced hos-
pital stays as compared to those who received standard
therapy alone. Benefits of levosimendan were apparent as
early as 6 h and persisted for at least 5 days, even though the
drug was infused for only 24 h. Unfortunately, the significant
symptomatic benefit was countered by an increased risk of
serious adverse cardiovascular events. These adverse events
included hypotension, headache, atrial and ventricular
tachyarrhythmias. The most disturbing result was numeri-
cally increased (though insignificant) mortality with a hazard
ratio of 1.26 in the levosimendan group. The relative risk of
death was greatest in patients who needed inotropes the
most that is patients with a pre-treatment systolic blood
pressure <100 mmHg (relative risk 1.9). Due to serious
adverse events and trend towards increased mortality espe-
cially in sicker patients, levosimendan will only have a
limited role in the management of patients with ADHF. Based
on the current evidence, role of levosimendan should be
restricted to patients with ADHF with systolic blood pressure
>100 mmHg who remain symptomatic despite conventional
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Background: Cardiotoxicity is an important and a common
complication of cancer chemotherapeutic drugs. It may not
only be associated with significant morbidity and mortality
but also often becomes a limiting factor in adequate anti-
cancer treatment. Several pharmacological agents are being
evaluated for their efficacy in preventing cardiotoxicity of the
cancer drugs.
Material and methods:Ninety patients with hematological
malignancies undergoing chemotherapy and/or autologous
hematopoietic stem cell transplantation (HSCT) were
recruited in this study and were randomized to receive a
combination of enalapril and cardvedilol (intervention arm) or
no intervention (control arm). Comprehensive echocardiog-
raphy and cardiac magnetic resonance imaging (MRI) were
performed at baseline and at 6 months after randomization.
The primary efficacy endpoint was the absolute change from
baseline in left ventricular ejection fraction (LVEF).
Results: The mean age of the study subjects was 50  13
years. By the end of the 6 months, there was a significant fall
in LVEF in controls (3.28% absolute reduction from baseline)
but no change was seen in the intervention group. As a result,
at 6 months, LVEF was significantly lower in the control group
in comparison to the intervention group (an absolute differ-
ence of 3.1% by echocardiography and 3.4% by cardiac MRI,
p¼ 0.035 and 0.09, respectively). The beneficial effect was seen
almost exclusively in patients receiving chemotherapy alone
(absolute difference in LVEF of 6.38% at 6 months, p ¼ 0.025)
and not in those undergoing HSCT (absolute difference of
1.01%, p ¼ 0.56). In addition, compared to controls, patients in
the intervention group had a lower incidence of the combined
event of death or heart failure (6.7% vs. 22%, p ¼ 0.036) and of
death, heart failure, or a final LVEF <45% (6.7% vs. 24.4%,
p ¼ 0.02).
Conclusions: The present trial showed that a combination
of enalapril and carvedilol might prevent cardiotoxicity in
patients undergoing chemotherapy for hematological
malignancies.1. Perspective
Advancements in cancer treatment have allowed improved
prognosis and better survival in patients undergoing
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cancer chemotherapeutic agents are associated with sig-
nificant side-effects which often nullify the gains achieved in
terms of improved cancer outcomes. Cardiotoxicity is one of
the most important complications of cancer chemotherapy
and may be associated with significant morbidity and mor-
tality. Anthracyclines and monoclonal antibody-based tyro-
sine kinase inhibitors are the two agents most notorious for
causing cardiotoxicity.
Several different approaches are being evaluated for
preventing development of cancer chemotherapy-related
cardiotoxicity. Thorough pre-treatment cardiac evaluation
to identify patients with pre-existing cardiac diseases or
those at risk of developing cardiotoxicity and limiting the
maximum dose of the potentially cardiotoxic agents are
very helpful in reducing the likelihood of cardiotoxicity
associated with cancer treatment. Nonetheless, cardiotox-
icity can develop even in patients without pre-existing
cardiac illness and is not always dose-dependent, thus
limiting our ability to prevent cardiotoxicity with reason-
able certainty. Consequently, several alternative
approaches are being evaluated to prevent cancer
chemotherapy-related cardiotoxicity. Animal experiments
and initial human studies, most of which were non-
randomized, have shown that many of the cardiac drugs
such as angiotensin converting enzyme inhibitors (ACEI),
beta blockers and statins may be helpful in preventive
cardiotoxicity with cancer drugs. To this effect, the present
study by Bosch et al represents a well-performed random-
ized trial, which showed that a combination of enalapril (an
ACEI) and carvedilol (a beta blocker) was effective in
preventing development of LV systolic dysfunction in
patients receiving intensive chemotherapy for hemato-
logical malignancies. The therapy was also effective in
improving clinical outcomes in this patient population. The
reason why patients undergoing HSCT did not derive much
benefit was related to the fact that they did not receive
prolonged chemotherapeutic treatment and were therefore
at low risk of having cardiotoxicity. A strong point of the
study was that the changes in LVEF were assessed by both
echocardiography and cardiac MRI, which improved the
reliability of the study findings. However, the major limi-
tation of the study was its small sample size. In addition,
the magnitude of the benefit observed in this study was
small, in part because of the fact that only the patients with
normal LVEF and no cardiac illness at baseline were
included. Thus, while this study has shown encouraging
findings, larger studies are required to confirm these find-
ings and to also assess role of these agents in preventing
cardiotoxicity in different types of malignancies and with
different chemotherapeutic agents.
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their components originating from the oral cavity or respira-
tory tract, have been suggested to contribute to inflammation
in the coronary plaque, leading to rupture and the subsequent
development of coronary thrombus. We aimed to measure
bacterial DNA in thrombus aspirates of patients with ST-seg-
ment-elevation myocardial infarction and to check for a pos-
sible association between bacteria findings and oral pathology
in the same cohort.
Methods and results: Thrombus aspirates and arterial
blood from patients with ST-segment-elevation myocardial
infarction undergoing primary percutaneous coronary inter-
vention (n ¼ 101; 76% male; mean age, 63.3 years) were ana-
lyzed with real-time quantitative polymerase chain reaction
with specific primers and probes to detect bacterial DNA from
several oral species and Chlamydia pneumoniae. The median
value for the total amount of bacterial DNA in thrombi was 16
times higher than that found in their blood samples. Bacterial
DNA typical for endodontic infection, mainly oral viridans
streptococci, was measured in 78.2% of thrombi, and perio-
dontal pathogens were measured in 34.7%. Bacteria-like
structures were detected by transmission electron micro-
scopy in all 9 thrombus samples analyzed; whole bacteria
were detected in 3 of 9 cases. Monocyte/macrophage markers
for bacteria recognition (CD14) and inflammation (CD68) were
detected in thrombi (8 of 8) by immunohistochemistry. Among
the subgroup of 30 patients with myocardial infarction
examined by panoramic tomography, a significant association
between the presence of periapical abscesses and oral vir-
idans streptococci DNA-positive thrombi was found (odds
ratio, 13.2; 95% confidence interval, 2.11e82.5; p ¼ 0.004).
Conclusions: Dental infection and oral bacteria, especially
viridans streptococci, may be associated with the develop-
ment of acute coronary thrombosis.
1. Perspective
Poor dental hygiene has been linked to an increased risk of
cardiovascular diseases. A recent meta-analysis1 and a recent
large population study2 have shown a correlation between
coronary artery disease and dental health like alveolar bone
loss, pathological periodontal pockets and missing teeth.
However, there was no consensus on the most pathologically
relevant bacteria.
This study demonstrated that oral bacterial DNA, espe-
cially oral viridans streptococci, can be detected in the coro-
nary thrombus aspirates of patients with ST-elevation MI
undergoing primary PCI. Bacteria-like structures and compo-
nents were detected by transmission electronmicroscopy and
monocyte/macrophage markers for bacteria recognition
